Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interests: MIA, SJHV, AHN, PB, AHW, ARS, AMW, ATB, MC, PS, JC, NK, JM, KS, DES, PM, RL, PHH, MS, IMA, PC and ADK have no conflicts of interest to disclose. JHR was an employee by and a share-holder of GlaxoSmithKline. SB is an employee of Johnson & Johnson and a former employee of GlaxoSmithKline and holds stock in both companies.
Conflict of interests: SSW reports consulting fees from Kings College Hospital NHS Foundation Trust, Academic Medical Research, Aladdin Healthcare Technologies Ltd, AMC Medical Research BV, AMC Medical Research BV P402, Asthma UK, AstraZeneca AB, Athens Medical School, Autobedrijf Verfaillie V-CO BVBA, Boehringer Ingelheim International GmbH, Breathomix BV, Chiesi Farmaceutici S.p.A., CHU de Toulouse, CIRO, Consorcio Centro de Investigación Biomédica en Red, Dawi Iman Automobile, DS Biologicls Ltd, ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE, EFA- European Federation of Allergy, European Respiratory Society, European Society for Swallowing Disorders, F. HOFFMANN-LA ROCHE AG, FISEVI, Fluidic Analytics Ltd., Foundation for Research and Technology Hellas, Fraunhofer IGB, Fraunhofer ITEM, Fraunhofer-Institut für Produktionstechnologie IPT, GlaxosmithKline Research & Dev Ltd, Gossamer Bio, Inc, Holland & Knight, Imperial College, Institute for Computer Science and Control, Karolinska Institutet Fakturor, KU Leuven, Longfonds, Maastricht University, MedImmune LLC, Merck Sharp & Dohme Corp., National Heart & Lung Institute, Ninja Hoen, Novartis Pharma AG, OncoRadiomics S.A., Owlstone Medical Limited, PExA AB, Pulmonary Fibrosis Foundation, RISE Research Institutes of Sweden AB, Sanofi US Services Inc., TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D INC, The North West Lung Centre Charity, Three Lakes Foundation Trust, TopMD Precision Medicine Ltd, UCB Biopharma S.P.R.L., UCB Biosciences GmbH, UGent, Umeå University, Univ. Hosptial Southampton NHS Foundation Trust, Università Campus Bio-Medico di Roma, Universita Cattolica Del Sacro Cuore, Universität Ulm, Universitätsklinikum Würzburg, University College London, University Hospital Southampton, University of Bern, University of Edinburgh, University of Hull, University of Leicester, University of Loughborough, University of Luxembourg, University of Manchester, University of Notthingham, VITO NV, Vlaams Brabant, Dienst Europa, Kings College Hospital NHS Foundation Trust, and Academic Medical Research paid to his company (BioSci Consulting); outside the submitted work.
Conflict of interests: BDM, and CA have received grants from Innovative Medicines Initiative (IMI U-BIOPRED Grant N°115010 and IMI eTRIKS Grant n°115446), during the conduct of the study.
Conflict of interests: MU is an employee of AstraZeneca and holds shares in the company.
Conflict of interests: IH has received personal honoraria for lectures from AstraZeneca, Chiesi, GSK, Novartis, and MSD, and had unpaid leadership or fiduciary roles in European Respiratory Society, Hungarian Respiratory Society, and Hungarian Association of Medical Societies.
Conflict of interests: TS has received fees from lecturing for Boehringer-Ingelheim with payments done to clinic/institution.
Conflict of interests: SJF has received honoraria for lectures from AstraZeneca, Novartis, Teva, Boehringer Ingelheim and Chiesi, and has received support to attend ERS and BTS meetings from AstraZeneca and Chiesi, and participated in the advisory board of Cheisi.
Conflict of interests: RD is a co-founder of and has stocks with Synairgen, a University of Southampton spin out company, which is funding a phase 3 trial of nebulised interferon beta for treatment of hospitalised COVID-19 patients and a community based study of PCR positive individuals to see if treatment can improve clinical outcomes, and is am a member (without receving funding) of the Urgent Public Health (UPH) panel that approves studies under a priority badge, and has received fees for consultancy services from TEVA Pharmaceuticals, Sanofi, Boehringer and Novartis, and has received grants (paid to his institution) from IMI funded EU project, UBIOPRED, MRC funded project on COPD: COPD-MAP and Novartis to Study of mechanisms of action of Omalizumab, and has received fees for lectures on mechanisms of action of Xolair for Novartis and a lecture in symposium on mechanisms of asthma for Teva. PS is a shareholder in TopMD Precision Medicine.
Conflict of interests: FC reports funding during the conduct of the study paid to his institution from the Innovative Medicines Initiative (IMI) Joint Undertaking under grant agreement no. 115010.
Conflict of interests: PJS reports funding during the the conduct fo the study paid to his institution from Innovative Medicines Initiative (IMI), which is public-private funding provided by the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA), and is a scientific adviser and has an officially non-substantial interest in the start-up company Breathomix BV, The Netherlands; outside the submitted work.
Conflict of interests: AHM has received grants from Health Holland and she is the PI of a P4O2 (Precision Medicine for more Oxygen) public private partnership sponsored by Health Holland involving many private partners that contribute in cash and/or in kind (Boehringer Ingelheim, Breathomix, Fluidda, Ortec Logiqcare, Philips, Quantib-U, Smartfish, SODAQ, Thirona, TopMD and Novartis), and received unrestricted research grants from GSK, Boehringer Ingelheim and Vertex, and received consulting fees paid to her institution from Boehringer Ingelheim and Astra Zeneca, and received honoraria for lectures paid to her institution from GlaxosmithKline; outside the submitted work.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received July 27, 2021.
- Accepted October 11, 2021.
- Copyright ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org